Plain-English translation of NCT06624826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
During cataract surgery, doctors remove your cloudy natural lens and replace it with an artificial lens implant. This trial is testing a new lens called PureSee that's designed to help you see clearly at multiple distances—far away, at arm's length, and up close—so you may need glasses less often. The study will compare two different ways of setting up this lens in your eyes to find out which approach works best for you.
After cataract surgery, most people still need reading glasses for close-up work and computer use. This medication represents a newer technology that aims to reduce that need by providing clear vision across all distances without the side effects that some other premium lenses cause.
You would undergo cataract surgery in which your cloudy lens is removed and replaced with the PureSee implant. You would be randomly assigned to one of two groups: one group receives the lens set for standard distance vision (emmetropia), while the other group receives it set for monovision, which balances distance and near vision. After surgery, you would attend follow-up visits so doctors can measure how well you see at different distances and assess your overall satisfaction with the new lens.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
Austria
Sponsor
Prim. Prof. Dr. Oliver Findl, MBA
Enrollment target
~60 participants
Started
October 2024
Primary completion
October 2025
Age range
21 Years – 105 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Johannes Zeilinger, MD
Vienna Institute for Research in Ocular Surgery (VIROS)